Advanced search
Publication Cover
Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders Volume 1, 2000 - Issue 1
Journal homepage
89
Views
0
CrossRef citations to date
0
Altmetric
Research Article

How can physicians and their patients with ALS decide to use the newly-available treatments to slow disease progression?

Carmel Armon
Pages 3-14 | Published online: 10 Jul 2009

  • Kasarkis EJ, Winslow M. When did Lou Gehrig's personal illness begin? Neurology 1989; 39:1243-1245.
  • Gurney ME, Cutting FB, Zhai P, et al. Benefit of vitamin E, riluzole and gabapentin in a transgenic model of familial ALS. Ann Neurol 1996; 39:147-157.
  • World Federation of Neurology Research Croup on Neuromuscular Disease Subcommittee on Motor Neuron Disease. Airlie House Guidelines. Therapeutic Trials in Amyotrophic Lateral Sclerosis. J Neurol Sci 1995; 129(Suppl): 1-10.
  • Bromberg MB, Brooks BR. Issues in clinical trial design II: Selection of end point measures. Neurology 1996; 47(Suppl2):S100-S102.
  • Brooks BR. Natural history of ALS: Symptoms, strength, pulmonary function and disability. Neurology 1996; 47(Suppl2):S71-S82.
  • Brooks BR. Amyotrophic lateral sclerosis clinimetric scales guidelines for administration and scoring. In: Hemdon RM, ed. Handbook of clinical neurologic rating scales. Demos Vermande. 1997 New York, NY.
  • Fleming TR, DeMets DL Surrogate end points in clinical trials: Are we being misled? Ann Intern Med 1996; 125: 605-613.
  • The ALS CNTF Treatment Study (ACTS) Phase I-II Study Croup. The Amyotrophic Lateral Sclerosis Functional Rating Scale. Arch Neurol 1996; 53:141-147.
  • McGuire D, Garrison L, Armon C, et al and the SSNJV/CNTF ALS Study Group. Relationship of Tufts Quantitative Neuromuscular Examination (TQNE) and the Sickness Impact Profile (SIP) in measuring progression of amyotrophic lateral sclerosis (ALS). Neurology 1996; 47:1442-1444.
  • Armon C, Ponraj E. Comparing composite scores based on maximal voluntary isometric contraction (MVIC) and on semi-quantitative manual motor testing (SQMMT) in measuring limb strength in patients with amyotrophic lateral sclerosis (ALS). Neurology 1996; 47:1586-1587.
  • Pinto AC, Evangelista T, Carvalho M, Alves MA, Sales Luis ML Respiratory assistance with a non-invasive ventilator (Bipap) in MND/ALS patients: survival rates in a controlled trial. J Neurol Sci 1995; 129(Suppl): 19-26.
  • Kleopa KA, Neal B, Sherman M, Heiman-Patterson T. Bipap prolongs survival in patients with ALS. 9th International Symposium on ALS/MND. 1998. Munich, Germany.
  • Mazzini L, Corra T, Zaccala M, Mora G, Del Piano M, Galante M. Percutaneous endoscopie gastrostomy and enterai nutrition in amyotrophic lateral sclerosis. J Neurol 1995; 242: 695-698.
  • Andres PL, Finison LJ, Conlon T, Thibodeau LM, Munsat TL. Use of composite scores (megascores) to measure deficit in amyotrophic lateral sclerosis. Neurology 1998; 38: 405-408.
  • The National Isometric Muscle Strength (NIMS) Database Consortium. Muscular weakness assessment: use of normal isometric strength data. Arch Phys Med Rehabil 1996; 77: 1251-1255.
  • Hoagland RI, Mendoza PT, Armon C, et al. Reliability of maximal voluntary isometric contraction testing in a multicenter study of patients with amyotrophic lateral sclerosis. Muscle Nerve 1997; 20: 691-695.
  • Mayo Clinic. Clinical examinations in neurology. 5th edn. Philadelphia: WB Saunders, 1981:131.
  • Dyck PJ, Sherman WR, Halcher LM, et al. Human diabetic endoneurial sorbitol fructose, and myo-inositol related to sural nerve morphometry. Ann Neurol 1980; 8: 590-596.
  • Windebank AL, Litchy WJ, Daube JR, Iverson, RA. Lack of progression of neurologie deficit in survivors of paralytic polio: a 5-year prospective population-based study. Neurology 1996; 46: 80-84.
  • Appel V, Stewart SS, Smith C, Appel SH. A rating scale for amyotrophic lateral sclerosis: Description and preliminary experience. Ann Neurol 1987; 22:328-333.
  • Haverkamp LJ, Appel V. Appel SH. Natural history of amyotrophic lateral sclerosis in a database population. Brain 1995; 118:707-719.
  • Fahn S, Elton R. Unified Parkinson's Disease rating scale. In: Fahn S, Marsden C, eds. Recent developments in Parkinson's disease. New York, NY: Macmillan, 1987:153-163.
  • Hillel AD, Miller RM, Yorkston K, McDonald E, Morris FH, Konikow N. Amyotrophic lateral sclerosis severity scale. Neuroepidemiol 1989; 8: 142-150.
  • Third Symposium on Parkinson's Disease, held at the Royal College of Surgeons of Edinburgh, May 20-22, 1968. Edinburgh: Livingstone, 1969.
  • Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. A prospective study of acute cerebrovascular disease in the community: the Oxfordshire Community Stroke Project 1981-86.1 Neurol Neurosurg Psychiatry 1990; 53: 16-22.
  • Mahoney FI, Barthel DW. Functional evaluation: The Barthel Index. MD State Med 11965; 14: 61-65.
  • Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967; 17:427-442.
  • Testa MA, Simonson DC. Assessment of quality-of-life outcomes. N Engl J Med 1996; 334:835-840.
  • Patrick DL, Deyo RA. Generic and disease-specific measures in assessing health status and quality of life. Med Care 1989; 27: (3)(Suppl):S217-S231.
  • Dodson WE, Trimble MR. Epilogue: Quality of life in epilepsy. In: Trimble MR, Dodson WE, eds. Epilepsy and quality of life. New York: Raven Press 1994:259-265.
  • Damiano AM. The Sickness Impact Profile. Quality of life and pharmacoeconomics in clinical trials. 2nd edn. Spiker B, ed. Philadelphia, PA: Lippincott-Raven, 1996.
  • Cramer JA, Perrine K, Devinsky O, Meador K. A brief questionnaire to screen for quality of life in epilepsy: the QOLIE-10. Epilepsia 1996; 37: 577-582.
  • McGuire D, Garrison L, Armon C, et al. "Mini-SIP" quality of life indices correlate strongly with isometric muscular strength in measuring progression of ALS. 7th International Symposium on ALS/MND, 11-13 November 1996, Chicago, IL MND Association, Northampton, UK.
  • Bensimon G, Lacomblez L, Meininger V, for the ALS/Riluzole Study Group. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994; 330: 585-591.
  • Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V, for the Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 1996; 347: 1425-1431.
  • Lacomblez L, Bensimon B, Leigh PN, et al. A confirmatory dose-ranging study of riluzole in ALS. Neurology 1996; 47(Suppl 4): S242-S250.
  • Medical Economics Co Inc. 1997 Physician's Desk Reference. Motivate, NJ: Medical Economics Co, 1997:2198-2201.
  • Lange DI, Felice KI, Grewal MI, et al. A double-blind, placebo-controlled, therapeutic trial to assess the efficacy of recombinant human insulin-like growth hormone (rhICF-1). In: The treatment of amyotrophic lateral sclerosis: a multicenter, double-blind, placebo-controlled clinical study. 6th International Symposium on ALS/MND, Dublin, October, 1995. MND Association, Northampton, UK.
  • Borasio CD, Leigh PN, Robberecht W, and the European ALS/ICF-1 Study Croup. The European trial of insulin-like growth factor l in ALS: an update. 7th International Symposium on ALS/MND, Chicago, IL, November, 1996. MND Association, Northampton, UK.
  • Leigh N, and the North American and European ALS/ICF-I Study Croups. The treatment of ALS with recombinant human insulin-like growth factor I (rhICF-I): pooled analysis of two clinical trials. Neurology 1997; 48: A217-218.
  • Miller RC, Moore D, Young LA, et al. Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 1996; 47:1383-1388.
  • Neville HE, Brinkmann I, Murphy J, Miller RC, Moore D and WALS Study Croup. A comparison of two quantitative muscle strength measuring methods in the analysis of the ALS gabapentin trial data. 7th International Symposium on ALS/MND, Chicago, IL. November, 1996. MND Association, Northampton, UK.
  • ACTS CNFT Treatment Croup. A double-blind, placebo-controlled, clinical trial of subcutaneous recombinant human ciliary neurotrophic factor in ALS. Neurology 1996; 46: 1244-1249.
  • Miller RC, Petajan J, Bryan WW, et al. A placebo-controlled trial of recombinant human ciliary neurotrophic factor (rhCNTF) in amyotrophic lateral sclerosis. Ann Neurol 1996; 39: 256-260.
  • Bradley WG, for the BDNF Phase III Study Croup: A controlled trial of recombinant methionyl human BDNF in ALS: The BDNF Study Croup (Phase III). Neurology 1999; 52: 1427-1433.
  • Bradley WC and The BDNF Study Croup. Subcutaneous administration of recombinant brain-derived neurotrophic factor (r-metHuBDNF) in patients with amyotrophic lateral sclerosis. 6th International Symposium on ALS/MND, Dublin, October, 1995. MND Association, Northampton, UK.
  • Bryan WW, McIntire D, Camperiengo L, et al. Factors influencing the use of the riluzole by ALS patients. 8th International symposium on ALS/MND, Glasgow, 3-5 November 1997. MND Association, Northampton, UK.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.